Aldesleukin
- Generic Name
- Aldesleukin
- Brand Names
- Proleukin
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 110942-02-4
- Unique Ingredient Identifier
- M89N0Q7EQR
- Background
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
- Indication
For treatment of adults with metastatic renal cell carcinoma.
- Associated Conditions
- Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)
- Associated Therapies
- -
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
- First Posted Date
- 2007-01-04
- Last Posted Date
- 2017-02-20
- Target Recruit Count
- 17
- Registration Number
- NCT00418496
- Locations
- 🇺🇸
Ohio State University, Columbus, Ohio, United States
Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2006-12-22
- Last Posted Date
- 2021-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 26
- Registration Number
- NCT00414765
- Locations
- 🇺🇸
James Graham Brown Cancer Center, Louisville, Kentucky, United States
🇺🇸USC/Kenneth Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma
- Conditions
- First Posted Date
- 2005-11-08
- Last Posted Date
- 2008-04-21
- Lead Sponsor
- US Oncology Research
- Target Recruit Count
- 110
- Registration Number
- NCT00250861
- Locations
- 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸Pudget Sound Cancer Center-Seattle, Seattle, Washington, United States
🇺🇸Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States
Treating Patients With Childhood Acute Myeloid Leukemia With Interleukin-2
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2009-02-12
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 580
- Registration Number
- NCT00149162
- Locations
- 🇫🇷
Children Armand Trousseau Hospital, Paris, France
Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults
- Conditions
- First Posted Date
- 2005-05-11
- Last Posted Date
- 2008-08-08
- Target Recruit Count
- 24
- Registration Number
- NCT00110578
- Locations
- 🇺🇸
University of Washington (UW), Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer
- Conditions
- First Posted Date
- 2004-06-21
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT00005993
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1449
- Registration Number
- NCT00026312
- Locations
- 🇺🇸
Rady Children's Hospital - San Diego, San Diego, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UCSF Medical Center-Mission Bay, San Francisco, California, United States
Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
- Conditions
- First Posted Date
- 2002-05-30
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 21
- Registration Number
- NCT00038259
- Locations
- 🇺🇸
Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States
🇺🇸UCLA CARE Center CRS, Los Angeles, California, United States
🇺🇸UC Davis Medical Center, Sacramento, California, United States
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-05-21
- Target Recruit Count
- 110
- Registration Number
- NCT00000923
- Locations
- 🇺🇸
St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States
🇺🇸Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States
🇺🇸Case CRS, Cleveland, Ohio, United States
A Study of Zidovudine Plus Interleukin-2 in HIV-Infected Patients Who Have No Symptoms of Infection But Who Have Tender Lymph Nodes
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-04
- Target Recruit Count
- 30
- Registration Number
- NCT00001005
- Locations
- 🇺🇸
Duke Univ. Med. Ctr. Adult CRS, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.